Why Asthma Research Is Expanding Right Now
Something has shifted in asthma research over the past few years. Where doctors once relied almost entirely on inhaled corticosteroids and bronchodilators, pharmaceutical companies and academic medical centers are now pouring resources into targeted therapies that address the underlying immune pathways driving airway inflammation. A recent review of phase 2b and phase 3 randomized controlled trials found that biologic treatments reduced the annualized asthma exacerbation rate requiring hospitalization or emergency department visits by roughly 56% compared to placebo, a finding that has fueled an unprecedented wave of new studies across the country.
The landscape of asthma clinical trials in the United States now spans well over a hundred active sites. Major sponsors like AstraZeneca, Pfizer, and Eli Lilly are running multicenter studies that reach cities from Tempe, Arizona to Boston, Massachusetts. A phase 3b study investigating tezepelumab, for example, is exploring whether patients with severe asthma can safely reduce their background maintenance medications while maintaining symptom control. Meanwhile, Pfizer is enrolling adults aged 18 to 70 with uncontrolled moderate-to-severe asthma for a trial of a steroid-free investigational medicine, specifically targeting people who have needed oral steroids for an asthma attack within the past twelve months.
What makes this moment particularly interesting is the sheer variety of approaches being tested. Beyond the well-known biologics like dupilumab, mepolizumab, and benralizumab, newer compounds such as brenipatide and PRA-216 are entering phase 2 trials, each targeting different inflammatory pathways. For someone who has cycled through multiple inhalers without relief, enrolling in an asthma biologic clinical trial could mean accessing a treatment that addresses the specific type of inflammation driving their disease.
Who Can Participate and What to Expect
Eligibility varies from study to study, but a few patterns hold across most asthma clinical trial enrollment programs. Researchers typically look for adults aged 18 and older with a physician-confirmed asthma diagnosis who continue to experience symptoms despite using prescribed medications. Some trials focus on mild allergic asthma, while others specifically recruit people with severe, uncontrolled disease. One study at Mount Sinai Hospital in New York is enrolling World Trade Center-certified asthma patients aged 21 and older whose condition remains uncontrolled on controller medications. Another at UVA Health is screening adults aged 18 to 65 with mild allergic asthma for future respiratory challenge studies.
The screening process itself can feel like a thorough checkup. You might complete breathing tests, allergy skin testing, blood draws, and a review of your medical history. Screening visits are typically compensated separately. At UVA Health's Division of Asthma, Allergy, and Immunology, screening participants can receive up to $125 for completing the evaluation process, even if they do not ultimately qualify for a study.
Once enrolled, the commitment level depends heavily on the trial design. A study at Brigham and Women's Hospital Asthma Research Center in Boston, for instance, required 26 onsite visits over 22 months for participants in one of its longer-term trials. That is a significant time investment, and it is the kind of detail worth weighing honestly before signing a consent form. Missing appointments can lead to removal from a study, and not every trial fits every lifestyle.
The table below outlines the broad categories of asthma trials and what they typically involve:
| Trial Type | Example Focus | Typical Duration | Participant Profile | Key Benefit | What to Consider |
|---|
| Biologic (Phase 3) | Tezepelumab, Dupilumab | 12-24 months | Moderate-to-severe uncontrolled asthma | Access to targeted therapy | Frequent clinic visits required |
| Oral Medication (Phase 2) | Brenipatide, PRA-216 | 6-12 months | Mild-to-moderate asthma | Novel mechanism of action | Less established safety profile |
| Inhaler/Device Study | New delivery systems | 3-6 months | Mild persistent asthma | Shorter time commitment | May require washout of current meds |
| Observational Study | Biomarker research | Single visit or short-term | Any asthma type | Minimal disruption | No treatment access |
Compensation, Costs, and the Realities of Participation
One of the most common questions about asthma research study compensation is straightforward: what does it actually pay? Compensation structures vary widely, and they are designed to reimburse participants for time and travel rather than to serve as income. Screening visits might carry a payment in the range of $50 to $125 per visit. Longer studies with more demanding schedules can offer more substantial reimbursement. The Brigham and Women's Hospital study mentioned earlier compensated participants up to $3,900 over the full 22-month study period, with parking vouchers provided separately. Shorter focus groups or survey-based studies around inhaler use might offer gift cards in the $50 to $350 range.
It is important to understand that compensation reflects the burden of participation. A study requiring monthly infusions, blood draws, and symptom diaries will naturally offer more than one involving a single questionnaire. What participants consistently report, however, is that the value extends beyond the financial side. "The team treated me with so much care. I felt heard, respected, and informed every step of the way," one participant told Epic Medical Research, a clinical research organization that runs asthma trials across multiple states. Another added, "Being part of a clinical trial gave me hope. The doctors were incredible and I felt I was contributing to something bigger."
The investigational medication itself is provided at no cost during the trial, and study-related medical evaluations are covered by the research sponsor. Travel expenses, parking, and sometimes meals are reimbursed separately, though the specifics depend on the institution. Before enrolling, ask the study coordinator for a clear breakdown of what is covered and what you might need to handle yourself.
Finding a Trial That Fits Your Life
Searching for asthma clinical trials near me has become considerably easier with tools like ClinicalTrials.gov, which lists federally and privately funded studies with detailed eligibility criteria, locations, and contact information. Major research universities like UVA, Mount Sinai, and Brigham and Women's Hospital maintain their own trial directories, and contract research organizations such as Epic Medical Research and AMR Clinical operate sites in multiple states including Arizona, California, and Texas.
When evaluating a trial, several practical questions can help you decide whether it is right for you. How many visits does the study require, and how long is each one? Is the site reasonably close to where you live or work? Will you need to take time off from your job? What happens if your asthma worsens during the study? Reputable research teams will walk you through these details during the informed consent process, and you should never feel rushed into signing.
A growing number of researchers are also working to make trials more accessible to communities that have historically been underrepresented in asthma research. A qualitative study of UK and US researchers published in 2025 highlighted the importance of building long-term relationships, offering financial reimbursement, and paying attention to logistical barriers like language and location. These efforts are gradually reshaping who gets to participate in—and benefit from—asthma research.
For those considering their next step, the Asthma and Allergy Foundation of America maintains a resource page that connects patients with active studies, and many local pulmonology practices can point you toward trials recruiting in your area. Whether you have mild allergic asthma and are curious about a short-term screening study, or you live with severe uncontrolled disease and are looking for a biologic trial that might finally bring relief, the research community is actively looking for participants like you. The decision to enroll is personal, but the information you need to make it is more accessible than ever.
研究の知恵